TN2010000128A1 - Antibodies specific for the protofibril form of beta-amyloid protein - Google Patents

Antibodies specific for the protofibril form of beta-amyloid protein

Info

Publication number: TN2010000128A1
Authority: TN; Tunisia
Prior art keywords: béta; amyloid peptide; isolated antibodies; protofibril form; beta
Prior art date: 2007-11-16

Application number

TNP2010000128A

Other languages

English (en)

Inventor

Jeffrey Ravetch

Hidehiro Fukuyama

Original Assignee

Univ Rockefeller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-16

Filing date

2010-03-22

Publication date

2011-09-26

2010-03-22 Application filed by Univ Rockefeller filed Critical Univ Rockefeller

2011-09-26 Publication of TN2010000128A1 publication Critical patent/TN2010000128A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Plant Pathology (AREA)
Epidemiology (AREA)
Mycology (AREA)

TNP2010000128A 2007-11-16 2010-03-22 Antibodies specific for the protofibril form of beta-amyloid protein TN2010000128A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US98848107P	2007-11-16	2007-11-16
US1974708P	2008-01-08	2008-01-08
PCT/US2008/083659 WO2009065054A2 (fr)	2007-11-16	2008-11-14	Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde

Publications (1)

Publication Number	Publication Date
TN2010000128A1 true TN2010000128A1 (en)	2011-09-26

Family

ID=40639468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000128A TN2010000128A1 (en)	2007-11-16	2010-03-22	Antibodies specific for the protofibril form of beta-amyloid protein

Country Status (33)

Country	Link
US (3)	US8470321B2 (fr)
EP (2)	EP2207568B1 (fr)
JP (3)	JP5616230B2 (fr)
KR (3)	KR101478995B1 (fr)
CN (1)	CN102006887B (fr)
AU (1)	AU2008322523B2 (fr)
BR (1)	BRPI0819312A2 (fr)
CA (1)	CA2705582A1 (fr)
CO (1)	CO6270277A2 (fr)
CR (1)	CR11350A (fr)
CY (1)	CY1119376T1 (fr)
DK (1)	DK2207568T3 (fr)
DO (1)	DOP2010000097A (fr)
EA (1)	EA201000809A1 (fr)
ES (1)	ES2639016T3 (fr)
HK (1)	HK1244823A1 (fr)
HR (1)	HRP20171292T1 (fr)
HU (1)	HUE033825T2 (fr)
IL (1)	IL204542A (fr)
LT (1)	LT2207568T (fr)
MA (1)	MA31890B1 (fr)
ME (1)	ME01026B (fr)
MX (2)	MX2010003828A (fr)
MY (1)	MY158903A (fr)
NI (1)	NI201000046A (fr)
NZ (1)	NZ583632A (fr)
PL (1)	PL2207568T3 (fr)
PT (1)	PT2207568T (fr)
SG (1)	SG2014011183A (fr)
SI (1)	SI2207568T1 (fr)
TN (1)	TN2010000128A1 (fr)
WO (1)	WO2009065054A2 (fr)
ZA (1)	ZA201002592B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
RU2429244C2 (ru)	2006-03-23	2011-09-20	Байоарктик Ньюросайенс Аб	Улучшенные селективные в отношении протофибрилл антитела и их применение
PT2436696T (pt) *	2007-01-05	2017-08-21	Univ Zuerich	Anticorpo anti-beta-amiloide e usos do mesmo
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
ES2639016T3 (es)	2007-11-16	2017-10-25	The Rockefeller University	Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide
NZ593964A (en)	2008-12-19	2012-12-21	Univ Zuerich	Human anti-alpha-synuclein autoantibodies
FR2945538B1 (fr) *	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
DK2448968T3 (da) *	2009-06-29	2021-04-12	Bioarctic Ab	ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER
US10266585B2 (en)	2009-08-28	2019-04-23	The Board Of Regents Of The Univerity Of Texas System	Methods of treating brain injury
NZ598685A (en)	2009-09-11	2013-05-31	Probiodrug Ag	Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2012011621A1 (fr) *	2010-07-23	2012-01-26	Gwangju Institute Of Science And Technology	Clairance d'amyloïde bêta
CA2817973C (fr) *	2010-10-15	2019-06-25	The Board Of Regents Of The University Of Texas System	Anticorps qui lient des oligomeres amyloides
AR085302A1 (es)	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
AU2012272790B2 (en)	2011-06-23	2016-10-06	Biogen International Neuroscience Gmbh	Anti-alpha synuclein binding molecules
WO2013075740A1 (fr)	2011-11-23	2013-05-30	Sanofi	Procédé de purification d'anticorps
JP2013159596A (ja) *	2012-02-08	2013-08-19	Nihon Univ	β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体
DK3269736T3 (da) *	2012-05-10	2020-01-13	Georg August Univ Goettingen Stiftung Oeffentlichen Rechts Univsmedizin	Konformationsspecifikke antistoffer mod oligomerer af amyloid beta
EP2674495A1 (fr)	2012-06-14	2013-12-18	Sanofi	Système d'expression dans CHO
KR102272851B1 (ko)	2013-05-06	2021-07-02	사노피	항체를 정제하기 위한 연속 다단계 공정
WO2015051159A1 (fr) *	2013-10-02	2015-04-09	The Rockefeller University	Anticorps de protofibrilles amyloïdes et leurs procédés d'utilisation
MA53887A (fr) *	2014-07-10	2021-10-27	Bioarctic Ab	Anticorps à liaison protofibrille a-bêta améliorée
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US10772969B2 (en)	2015-11-09	2020-09-15	The University Of British Columbia	N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
JP7448174B2 (ja)	2015-11-09	2024-03-12	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
CN108350050A (zh) *	2015-11-09	2018-07-31	英属哥伦比亚大学	淀粉样蛋白β中的表位及其构象选择性抗体
HK1259324A1 (zh) *	2015-11-09	2019-11-29	英属哥伦比亚大学	淀粉样蛋白β表位及其抗体
DE102016005169B3 (de) *	2016-04-29	2017-07-13	Forschungszentrum Jülich GmbH	Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation
CN116333108A (zh) *	2016-07-18	2023-06-27	英属哥伦比亚大学	淀粉样蛋白β的抗体
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3354278A1 (fr) *	2017-01-31	2018-08-01	Sanofi	Effet de protection des cellules neuronales d'anticorps spécifiques de la forme protofibrillaire du peptide bêta-amyloïde
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
JP7368856B2 (ja)	2017-07-25	2023-10-25	トゥルーバインディング，インコーポレイテッド	Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
HRP20230387T1 (hr)	2017-08-22	2023-07-07	Biogen Ma Inc.	Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela
DK3461819T3 (da)	2017-09-29	2020-08-10	Probiodrug Ag	Inhibitorer af glutaminylcyklase
CN111315759B (zh) *	2017-10-12	2023-10-13	E&S医疗保健有限公司	硫氧还蛋白1表位及与其特异性结合的单克隆抗体
CA3100896C (fr) *	2018-05-30	2023-08-29	National Health Research Institutes	Anticorps anti-abeta et leurs utilisations
AU2020206593A1 (en)	2019-01-09	2021-07-15	Centre National De La Recherche Scientifique	Transferrin receptor-binding molecules, conjugates thereof and their uses
TW202110878A (zh)	2019-05-16	2021-03-16	法商賽諾菲公司	在神經系統中表現抗原結合蛋白
US20220251518A1 (en) *	2019-07-08	2022-08-11	Terumo Kabushik Kaisha	Hybridoma, method for making the same, monoclonal antibody, and method for making the same
WO2021035033A1 (fr) *	2019-08-20	2021-02-25	The Curators Of The University Of Missouri	Anticorps anti-amyloïdes bêta
EP4157338A4 (fr)	2020-05-26	2024-11-13	TrueBinding, Inc.	Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
CA3186614A1 (fr)	2020-07-23	2022-01-27	Michael SKOV	Anticorps anti-abeta
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
WO2022251048A1 (fr)	2021-05-24	2022-12-01	Eli Lilly And Company	Anticorps anti-amyloïde bêta et leurs utilisations
EP4399218A4 (fr) *	2021-08-30	2025-10-29	Brigham & Womens Hospital Inc	Procédés et matériels pour traiter une maladie neurodégénérative
CN114544940B (zh) *	2022-02-21	2024-09-24	中国海洋大学	一种用于快速检测透明质酸的胶体金试纸条
KR102530956B1 (ko) *	2022-09-08	2023-05-11	주식회사 알츠코리아	아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN120513256A (zh) *	2023-01-20	2025-08-19	迈威(美国)生物治疗有限公司	抗淀粉样蛋白β原纤丝/低聚物抗体和其用途
EP4480965A1 (fr)	2023-06-22	2024-12-25	Vect-Horus	Molécules de liaison au récepteur de transferrine, leurs conjugués et leurs utilisations pour prévenir ou traiter des maladies du snc
WO2024261333A1 (fr)	2023-06-22	2024-12-26	Vect-Horus	Molécules de liaison au récepteur de la transferrine, leurs conjugués et leurs utilisations pour prévenir ou traiter des maladies du système nerveux

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en)	1984-12-06	1987-01-13	Biomatrix, Inc.	Cross-linked gels of hyaluronic acid and products containing such gels
US5869620A (en) *	1986-09-02	1999-02-09	Enzon, Inc.	Multivalent antigen-binding proteins
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
SG48759A1 (en)	1990-01-12	2002-07-23	Abgenix Inc	Generation of xenogenic antibodies
GB9206318D0 (en)	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es)	1990-08-29	2006-02-16	Genpharm International, Inc.	Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
DE69230142T2 (de)	1991-05-15	2000-03-09	Cambridge Antibody Technology Ltd.	Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5962255A (en)	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5872215A (en)	1991-12-02	1999-02-16	Medical Research Council	Specific binding members, materials and methods
DK1024191T3 (da)	1991-12-02	2008-12-08	Medical Res Council	Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
EP2275089A1 (fr)	1993-11-19	2011-01-19	Alkermes Controlled Therapeutics, Inc.	Préparastion de microparticules biodégradables contentant un agent biologiquement actif
EP0977991A4 (fr)	1997-03-03	2004-12-15	Bristol Myers Squibb Co	Anticorps monoclonaux pour le cd6 humain
US6656508B2 (en)	1997-04-17	2003-12-02	Amgen Inc.	Sustained-release alginate gels
CA2293632C (fr)	1997-06-12	2011-11-29	Research Corporation Technologies, Inc.	Polypeptides d'anticorps artificiels
JP2001522812A (ja)	1997-11-07	2001-11-20	カイロンコーポレイション	Ｉｇｆ−１持続放出性処方物の作製方法
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6541033B1 (en)	1998-06-30	2003-04-01	Amgen Inc.	Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en)	1998-12-23	2002-09-17	Amgen Inc	Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
CA2349434A1 (fr) *	1999-09-03	2001-03-15	Ramot University Authority For Applied Research & Industrial Development Ltd.	Agents et compositions et procedes utilisant lesdits agents et lesdites compositions pour le diagnostic et/ou le traitement ou la prevention des maladies formant des plaques.
US6953593B2 (en)	2000-02-01	2005-10-11	Lipoprotein Technologies, Inc.	Sustained-release microencapsulated delivery system
EP3150633A1 (fr) *	2000-02-24	2017-04-05	Washington University St. Louis	Anticorps humanisés de séquestration d'une protéine bêta-amyloïde
AU7487301A (en)	2000-05-22	2001-12-03	Univ New York	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
EP2082749A3 (fr)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prévention et traitement de la maladie d'Alzheimer
AU1325102A (en)	2000-10-16	2002-04-29	Phylos Inc	Protein scaffolds for antibody mimics and other binding proteins
WO2002053739A2 (fr) *	2000-11-15	2002-07-11	Zymogenetics, Inc.	Homologue zcub5 de neuropiline
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
CA2444569C (fr)	2001-04-18	2011-01-04	Nostrum Pharmaceuticals Inc.	Nouvel enrobage de composition pharmaceutique a liberation lente
CN102659946A (zh) *	2002-03-13	2012-09-12	拜奥根Idec马萨诸塞公司	抗αvβ6抗体
CA2492671C (fr)	2002-03-22	2012-04-17	Aprogen, Inc.	Anticorps humanise et procede de preparation correspondant
US8871447B2 (en) *	2002-09-12	2014-10-28	The Regents Of The University Of California	Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US7063725B2 (en)	2002-10-21	2006-06-20	Sdgi Holdings, Inc.	Systems and techniques for restoring and maintaining intervertebral anatomy
US20040223970A1 (en) *	2003-02-28	2004-11-11	Daniel Afar	Antibodies against SLC15A2 and uses thereof
US20050124016A1 (en) *	2003-08-01	2005-06-09	Enh Research Institute	Antibodies specific for toxic amyloid beta protein oligomers
CA2437639C (fr)	2003-08-11	2016-07-05	Valera Pharmaceuticals, Inc.	Dispositifs de distribution de medicaments a long terme dotes de polymeres a base de polyurethane et leur fabrication
US20070110750A1 (en) *	2003-09-12	2007-05-17	The Regents Of The University Of California	Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20050187631A1 (en)	2004-01-27	2005-08-25	Sdgi Holdings, Inc.	Prosthetic device
SE0401601D0 (sv) *	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
CA2593846A1 (fr)	2005-01-14	2006-08-10	The Regents Of The University Of California	Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen
EP1841455A1 (fr)	2005-01-24	2007-10-10	Amgen Inc.	Anticorps anti-amyloide humanise
CA2619725C (fr) *	2005-08-18	2016-06-07	Ramot At Tel Aviv University Ltd.	Anticorps monocatenaires diriges contre le peptide beta-amyloide
KR101906161B1 (ko)	2005-11-30	2018-10-11	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2429244C2 (ru) *	2006-03-23	2011-09-20	Байоарктик Ньюросайенс Аб	Улучшенные селективные в отношении протофибрилл антитела и их применение
TWI557136B (zh) *	2007-06-12	2016-11-11	Ａｃ免疫公司	特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
ES2639016T3 (es)	2007-11-16	2017-10-25	The Rockefeller University	Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide
FR2945538B1 (fr)	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.

2008
- 2008-11-14 ES ES08849467.9T patent/ES2639016T3/es active Active
- 2008-11-14 EP EP08849467.9A patent/EP2207568B1/fr not_active Not-in-force
- 2008-11-14 HU HUE08849467A patent/HUE033825T2/en unknown
- 2008-11-14 MX MX2010003828A patent/MX2010003828A/es active IP Right Grant
- 2008-11-14 CN CN200880116438.9A patent/CN102006887B/zh not_active Expired - Fee Related
- 2008-11-14 US US12/738,955 patent/US8470321B2/en not_active Expired - Fee Related
- 2008-11-14 MY MYPI2010001497A patent/MY158903A/en unknown
- 2008-11-14 PT PT88494679T patent/PT2207568T/pt unknown
- 2008-11-14 MX MX2012010835A patent/MX335965B/es unknown
- 2008-11-14 AU AU2008322523A patent/AU2008322523B2/en not_active Ceased
- 2008-11-14 DK DK08849467.9T patent/DK2207568T3/en active
- 2008-11-14 WO PCT/US2008/083659 patent/WO2009065054A2/fr not_active Ceased
- 2008-11-14 LT LTEP08849467.9T patent/LT2207568T/lt unknown
- 2008-11-14 EA EA201000809A patent/EA201000809A1/ru unknown
- 2008-11-14 PL PL08849467T patent/PL2207568T3/pl unknown
- 2008-11-14 KR KR1020137010598A patent/KR101478995B1/ko not_active Expired - Fee Related
- 2008-11-14 ME MEP-2010-76A patent/ME01026B/fr unknown
- 2008-11-14 CA CA2705582A patent/CA2705582A1/fr not_active Abandoned
- 2008-11-14 EP EP17173145.8A patent/EP3257865A1/fr not_active Withdrawn
- 2008-11-14 HR HRP20171292TT patent/HRP20171292T1/hr unknown
- 2008-11-14 KR KR1020147029636A patent/KR101581733B1/ko not_active Expired - Fee Related
- 2008-11-14 JP JP2010534239A patent/JP5616230B2/ja not_active Expired - Fee Related
- 2008-11-14 NZ NZ583632A patent/NZ583632A/en not_active IP Right Cessation
- 2008-11-14 SI SI200831857T patent/SI2207568T1/sl unknown
- 2008-11-14 BR BRPI0819312-6A patent/BRPI0819312A2/pt not_active Application Discontinuation
- 2008-11-14 KR KR1020107011148A patent/KR101377535B1/ko not_active Expired - Fee Related
- 2008-11-14 SG SG2014011183A patent/SG2014011183A/en unknown
2010
- 2010-03-16 IL IL204542A patent/IL204542A/en active IP Right Grant
- 2010-03-22 TN TNP2010000128A patent/TN2010000128A1/fr unknown
- 2010-04-07 NI NI201000046A patent/NI201000046A/es unknown
- 2010-04-07 DO DO2010000097A patent/DOP2010000097A/es unknown
- 2010-04-07 CR CR11350A patent/CR11350A/es unknown
- 2010-04-07 CO CO10039830A patent/CO6270277A2/es not_active Application Discontinuation
- 2010-04-14 ZA ZA2010/02592A patent/ZA201002592B/en unknown
- 2010-05-17 MA MA32845A patent/MA31890B1/fr unknown
2011
- 2011-01-21 HK HK18104106.3A patent/HK1244823A1/en unknown
2013
- 2013-05-28 US US13/903,081 patent/US9340607B2/en not_active Expired - Fee Related
2014
- 2014-06-30 JP JP2014135187A patent/JP2014223074A/ja active Pending
2016
- 2016-05-16 US US15/155,275 patent/US20160319006A1/en not_active Abandoned
2017
- 2017-08-30 CY CY20171100918T patent/CY1119376T1/el unknown
2018
- 2018-03-22 JP JP2018054674A patent/JP2018140988A/ja active Pending

Also Published As

Publication number	Publication date
EA201000809A1 (ru)	2010-12-30
BRPI0819312A2 (pt)	2020-09-15
JP2018140988A (ja)	2018-09-13
PT2207568T (pt)	2017-09-01
IL204542A0 (en)	2010-11-30
CY1119376T1 (el)	2018-02-14
MX335965B (es)	2016-01-05
US20130315917A1 (en)	2013-11-28
CN102006887B (zh)	2016-02-03
HUE033825T2 (en)	2018-01-29
JP2011504360A (ja)	2011-02-10
EP2207568A2 (fr)	2010-07-21
MX2010003828A (es)	2010-04-27
CA2705582A1 (fr)	2009-05-22
CR11350A (es)	2010-06-21
EP2207568B1 (fr)	2017-05-31
LT2207568T (lt)	2017-12-11
CN102006887A (zh)	2011-04-06
US20160319006A1 (en)	2016-11-03
SI2207568T1 (sl)	2017-11-30
US20100209422A1 (en)	2010-08-19
IL204542A (en)	2016-03-31
PL2207568T3 (pl)	2018-01-31
US9340607B2 (en)	2016-05-17
KR20130051021A (ko)	2013-05-16
AU2008322523B2 (en)	2013-10-10
KR20140141671A (ko)	2014-12-10
KR101581733B1 (ko)	2015-12-31
AU2008322523A1 (en)	2009-05-22
DK2207568T3 (en)	2017-09-18
ZA201002592B (en)	2011-05-25
SG2014011183A (en)	2014-06-27
NZ583632A (en)	2012-05-25
ME01026B (fr)	2012-10-20
EP3257865A1 (fr)	2017-12-20
CO6270277A2 (es)	2011-04-20
MA31890B1 (fr)	2010-12-01
HRP20171292T1 (hr)	2017-12-15
KR101377535B1 (ko)	2014-03-27
WO2009065054A2 (fr)	2009-05-22
EP2207568A4 (fr)	2013-01-09
US8470321B2 (en)	2013-06-25
JP2014223074A (ja)	2014-12-04
NI201000046A (es)	2011-01-10
ES2639016T3 (es)	2017-10-25
WO2009065054A3 (fr)	2009-12-30
MY158903A (en)	2016-11-30
KR101478995B1 (ko)	2015-01-12
KR20100074297A (ko)	2010-07-01
HK1244823A1 (en)	2018-08-17
JP5616230B2 (ja)	2014-10-29
DOP2010000097A (es)	2016-12-30

Publication	Publication Date	Title
TN2010000128A1 (en)	2011-09-26	Antibodies specific for the protofibril form of beta-amyloid protein
MX2009003468A (es)	2009-04-15	Anticuerpo humanizado contra beta amiloide.
EA200800007A1 (ru)	2008-04-28	Фармацевтические композиции на основе нейроактивного стероида и их применение
MX338122B (es)	2016-04-04	Epitopes terapeuticos y usos de los mismos.
MX2009013503A (es)	2010-01-27	Anticuerpo monoclonal anti-amiloide-beta.
MX2007013626A (es)	2008-01-24	Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
PH12011502389B1 (en)	2016-01-11	Monoclonal antibody
WO2008067464A3 (fr)	2008-12-04	NOUVEAUX ANTICORPS MONOCLONAUX ANTI-GLOBULOMÈRE Aβ À AFFINITÉ POUR LE CONFORMÈRE Aβ
WO2008060364A3 (fr)	2009-02-19	Anticorps
EP2535355A3 (fr)	2013-02-20	Anticorps diriges contre CD38 pour le traitement du myelome multiple
IN2013MN00600A (fr)	2015-06-12
WO2009149486A3 (fr)	2010-06-10	Composés destinés au traitement de maladies
EP4279140A3 (fr)	2024-01-31	Anticorps humains du facteur tissulaire
WO2006035237A3 (fr)	2006-08-03	Procedes et compositions lies a la maladie d'alzheimer
MX2011010353A (es)	2011-12-06	Composicion farmaceutica.
CA2821268C (fr)	2021-06-15	Anticorps monoclonal humain ayant une specificite pour la proteine e du virus de la dengue de serotype 1 et utilisations de celui-ci
GEP20135826B (en)	2013-05-27	Novel antibodies used to treat cancer
WO2008122441A3 (fr)	2009-01-29	Anticorps anti-amyloïdes et leur utilisation pour le diagnostic et le traitement de maladies amyloïdes
NZ594347A (en)	2012-09-28	Antibodies against human tweak and uses thereof
WO2007140011A3 (fr)	2008-08-21	Cellules progénitrices érythroïdes et procédés de production du parvovirus b19 dans ces cellules
WO2010135521A3 (fr)	2011-05-05	Compositions et procédés pour le traitement et le diagnostic de la grippe
BRPI0513317A (pt)	2008-05-06	ciclosporinas para tratar doença de alzheimer
WO2009087467A3 (fr)	2009-12-17	Anticorps monoclonaux et leurs fragments de liaison dirigés contre le récepteur de la mélanocortine-4, et leur utilisation dans le traitement de la cachexie et d'états et maladies s'y rapportant
WO2006137938A3 (fr)	2009-04-16	Fragments d'anticorps assurant la protection contre l'infection par des pathogenes, methodes d'utilisation de ces derniers
WO2008070284A3 (fr)	2008-10-23	Peptides bêta amyloïdes et procédés d'utilisations de ceux-ci